Ensysce Biosciences, Inc.
ENSC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.02 | 0.01 | 0.00 |
| FCF Yield | -29.09% | -55.12% | -47.61% | -7.64% |
| EV / EBITDA | 301.64 | 0.00 | -0.41 | 0.00 |
| Quality | ||||
| ROIC | -301.99% | -50.22% | -63.32% | -96.88% |
| Gross Margin | -499.25% | -40.25% | 100.00% | -191.69% |
| Cash Conversion Ratio | 0.50 | 1.56 | 0.88 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.54% | 35.31% | 31.94% | 27.34% |
| Free Cash Flow Growth | 26.49% | -58.54% | -123.46% | 25.11% |
| Safety | ||||
| Net Debt / EBITDA | -71.40 | 0.00 | 1.44 | 0.00 |
| Interest Coverage | -587.39 | -553.96 | -510.37 | -332.60 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -13.31 | 30.28 | 1.50 | -23.55 |